Phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Latest Information Update: 22 May 2013
At a glance
- Drugs 2-methoxyestradiol (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 13 Mar 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.